Evergreening isn’t just a legal tactic—it’s a business strategy designed to delay generic entry, extend revenue, and slow price competition.
And in pharma, delay is destiny.
If you’re a generic, biosimilar, or investor trying to time launches—or a bran…

GPT, Rosalind, and the Generic Drug Question: What OpenAI’s Life Sciences Model Actually Changes
The life sciences world is buzzing again—this time around OpenAI’s Rosalind and the broader push to apply large language models to drug discovery. The head…

The patent cliff isn’t just a pricing problem—it’s a timing problem.
Most pharma teams treat the “patent cliff” like an event: a date on the calendar when exclusivity ends and generic competition arrives. But the companies that win don’t wait for the c…

OpenAI’s GPT just did something that should make every pharma IP team sit up: it “smashed” drug patent cliffs—by accelerating the work that used to take years.
That’s the headline from DrugPatentWatch’s latest post on how GPT and Rosalind are being use…

Predict the Attack: How to Forecast Paragraph IV Filings and Neutralize “Skinny Label” Threats
In pharma, the most expensive surprises rarely arrive with a press release. They arrive quietly—through a filing.
Paragraph IV drug patent challenges and the…

Your drug patent doesn’t last “a fixed number of years” in the GCC. It lasts a moving target. Here’s how to know exactly how long.
If you’re in pharma—whether you’re a brand team, a generic competitor, or an investor—there’s a moment when the math stop…

Unlocking the Hidden Timeline: How Long Do Drug Patents Last in the GCC?
Imagine investing millions into developing a groundbreaking medication, only to find out that your exclusive rights could expire sooner than expected, or worse, that your competit…

Your competitor isn’t “just improving” the drug. They’re extending its life. Here are 4 signals to watch.
If you’re in pharma—whether you’re in BD, legal, strategy, or competitive intelligence—you already know the uncomfortable truth: the most dangerou…

Biopharma bizdev teams don’t lose deals because they lack ambition. They lose deals because they’re late—late to the regulatory reality, late to the commercial math, and late to the packaging timeline that can make or break a launch.
Here’s the uncomfo…

GPT, Rosalind, and the Real Question for Drug Development: What Changes—And What Doesn’t
OpenAI’s Life Sciences model—often discussed alongside “Rosalind”—has sparked a familiar wave of excitement: AI will accelerate drug discovery, shorten timelines, …